Embryonic blood vessels that produce blood stem cells can also make heart muscle cells
By Kim Irwin August 02, 2012 Category: Research
UCLA stem cell researchers have discovered a surprising and unexpected phenomenon in the embryonic endothelium, the thin layer of cells lining the interior of blood vessels, where blood stem cells are made during early development.
The scientists found that the lack of a single transcription factor — a type of gene that controls cell fate by regulating other genes — allows precursor cells in the endothelium that normally generate blood stem cells and blood progenitor cells in blood-forming tissues to become something else entirely: beating cardiomyocytes, or heart muscle cells.
"It was absolutely unbelievable," said Dr. Hanna Mikkola, the study's senior author. "These findings went beyond anything that we could have imagined. The microenvironment in the embryonic vasculature that normally gives rise to blood cells can generate cardiac cells when only one factor, Scl, is removed, essentially converting a hematopoietic organ into a cardiogenic organ."
The finding is important because it suggests that the endothelium can serve as a source of heart muscle cells. The research may provide a new understanding of how to make cardiac stem cells for use in regenerative medicine, said Mikkola, who is an associate professor of molecular, cell and developmental biology in the UCLA Life Sciences Division and a researcher with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.
The two-year study is published Aug. 3 in the peer-reviewed journal Cell.
The findings were so surprising, in fact, that Mikkola and her team did not want to believe the results until all subsequent assays proved the finding to be true, said Amelie Montel-Hagen, co-first author of the study and a postdoctoral fellow at UCLA.
"To make sure we had not switched the samples between blood-forming tissues and the heart, we ran the experiments again and repeatedly got the same results," Montel-Hagen said. "It turns out Scl acts as a conductor in the orchestra, telling the other genes in the endothelium who should be playing and who shouldn't be playing."
The team used microarray technology to determine which genes were "playing" in the embryonic endothelium to generate blood stem and progenitor cells and found that in the absence of Scl, the genes required for making cardiomyocytes were activated instead, said co-first study author Ben Van Handel, also a UCLA postdoctoral fellow.
The lone difference was that Scl was missing in the process that resulted in the fate switch between blood and heart.
"Scl has a known role as a master regulator of blood development, and when we removed it from the equation, no blood cells were made," Van Handel said. "That the removal of Scl resulted in fully functional cardiomyocytes in blood-forming tissues was unprecedented."
The team used the yolk sac — the first tissue where blood cells are made — from embryos that lacked Scl, and within four hours of plating on the culture dish, the tissue had generated beating cardiomyocytes. The team also found similar cardiomyocyte potential in Scl-deficient embryos in the endocardium that lines the heart chambers. They also looked for genetic signatures that would suggest that these endothelial precursors could potentially make other closely related tissues, such as skeletal muscle, bone or kidney, but found no evidence of such plasticity. The default fate of the endothelium was to make cardiomyocytes in the absence of Scl, Mikkola said.
The findings may also have implications for cell reprogramming, which generally calls for adding factors to induce cell-fate change, a process that can be problematic. It might be safer to suppress a factor like Scl to nudge cells into a cardiomyocyte fate, Mikkola said.
"This study opens new ways to think about what could be a potential source of cardiac stem cells," she said. "We now have a better understanding of how cardiac progenitor cells can be made and regulated, and this may one day lead us to a way to treat heart attacks by creating new heart muscle cells to replace those that were damaged."
Going forward, Mikkola and her team plan to investigate the developmental and regenerative potential of the endothelium-derived cardiac progenitor cells, and define the mechanisms by which Scl can at the same time activate one fate while suppressing another.
"These results call for future studies to examine the prospect of harnessing the latent cardiogenic potential in the vasculature for use in regenerative medicine and to investigate whether similar development plasticity exists in other major cell-fate decisions in the developing embryo," the study states.
The study was funded by a California Institute for Regenerative Medicine New Faculty Award; an NIH National Heart, Lung and Blood Institute grant (RO1 HL097766-01); an Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA Innovation Award; National Institutes of Health Ruth L. Kirschstein National Research Service Awards (GM07185 and T32 HL69766); the European Molecular Biology Organization; the Human Frontier Science Program; the Netherlands Organization for Scientific Research; the European Social Fund (Mobilitas); and a Center of Excellence in Molecular Hematology grant from the National Institute of Diabetes and Digestive and Kidney Diseases.
The Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research: UCLA's stem cell center was launched in 2005 with a UCLA commitment of $20 million over five years. A $20 million gift from the Eli and Edythe Broad Foundation in 2007 resulted in the renaming of the center. With more than 200 members, the Broad Stem Cell Research Center is committed to a multidisciplinary, integrated collaboration among scientific, academic and medical disciplines for the purpose of understanding adult and human embryonic stem cells. The center supports innovation, excellence and the highest ethical standards focused on stem cell research with the intent of facilitating basic scientific inquiry directed toward future clinical applications to treat disease. The center is a collaboration of the David Geffen School of Medicine at UCLA, UCLA's Jonsson Cancer Center, the UCLA Henry Samueli School of Engineering and Applied Science and the UCLA College of Letters and Science.